AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01653678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D placebo
Study NCT01653678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Study NCT01653678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Study NCT02120833 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EpiCeram® Skin Barrier Emulsion
Description: Device (including sham) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
Study NCT02120833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal Oatmeal Cream
Description: Drug (including placebo) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
Study NCT01014988 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: zanamivir aqueous solution
Description: Zanamivir aqueous solution 10mg/mL is a clear, colorless, single use, sterile non-preserved preparation containing 10mg of zanamivir in each milliliter, and made isotonic with sodium chloride. It is presented in 20mL clear glass vials closed with rubber stoppers. Each vial contains 200mg of zanamivir.
Study NCT02460250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fibroscan
Description: All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked.
Study NCT01577953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB010
Description: Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.~Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board.~Dose levels:~Dose group A: 5 mg hgd40 in 2 mL solution (concentration: 2.5 mg/mL); Dose group B: 10 mg hgd40 in 2 mL solution (concentration: 5.0 mg/mL); Dose group C: 20 mg hgd40 in 2 mL solution (concentration: 10.0 mg/mL).
Study NCT01577953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.~Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board.
Study NCT02101736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: This is an open label Phase II clinical trial. For both cohorts, subjects will receive cabozantinib orally in continuous cycles. Each cycle is 28 days. In absence of progressive disease or dose limiting toxicity (DLT), subjects may continue therapy for a total of 24 cycles. Subjects with radiographic response (20% or greater reduction in tumor volume) at the end of 12 cycles can continue on therapy for up to an additional year. However, for Cohort A, subjects who do not achieve 15% reduction in tumor volume after 8 cycles will be considered treatment failure and taken off study. For Cohort B, the criteria that subjects who do not achieve 15% reduction by 8 cycles are considered treatment failure and taken off study was eliminated. Subjects will be carefully monitored for toxicities associated with cabozantinib.
Study NCT04235907 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation
Description: Internet-guided rehabilitation with weekly phone calls from a physical therapist.
Study NCT04235907 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: Prescription for physical therapy and a printed list of exercises to complete.
Study NCT04119895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation and core stabilization exercise
Description: In NMES group, the amplitude of the electrical current will be set at the highest level subject can tolerate.~The lumbar stabilization mode of the device will be used. This mode consists of three phases; warming, contraction and recovery phases. The duration will be set to 35 minutes. In the first 2 minutes (warming phase), frequency is 6 Hz. Contraction phase includes consecutive cycles of contractile frequency of 40 Hz for 6 seconds and the rest frequency of 4 Hz for 12 seconds, lasting a total of 30 minutes. The last 3 minutes (recovery phase) frequency is 3 Hz. The ramp up time is 2 seconds and the ramp down time is 1 second
Study NCT04119895 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham neuromuscular electrical stimulation and core stabilization exercise
Description: In sham NMES group, the amplitude of the electrical current will be set at a minimum level which does not stimulate any contraction.
Study NCT04406480 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: CGH-array and exome sequencing
Description: A blood sample will be used for CGH-array and exome sequencing
Study NCT02389257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINIMAG / MEG
Study NCT02389257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINIMAG / ECG
Study NCT02448940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Species of Lactobacillus
Description: 2 capsule a day Lactofem probiotics containing Species of Lactobacillus
Study NCT02448940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: lactose
Description: 2 capsule a day containing lactose
Study NCT04191629 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EO1404
Study NCT04191629 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endothelial brushing or Descemet stripping
Study NCT03718689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser etching
Description: Acid etching
Study NCT02953847 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rimactane
Description: 150 mg capsules, Sandoz MCC registration # A/20.2.3/784
Study NCT04447430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bright light
Description: treat patients with bright light, 30 min per day, 7 times per week, over 6 weeks
Study NCT04447430 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: dim red light
Description: treat patients with dim red light, 30 min per day, 7 times per week, over 6 weeks
Study NCT02249819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Soterix 1x1 anodal tDCS
Study NCT03611244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable seat device devised to maintain lumbar lordosis
Description: The posterior lumbar spine pads are used to maintain lumbar lordosis and fix it with the shoulder strap so that the hip does not slip forward (so that it does not become a sacral sitting posture).~The seat is equipped with a 5 cm air filled villus cushion to relieve pressure on the ischial tuberosity when sitting for a long time. The portable seat device can be moved so that the DMD can sit on the device even when sitting in a wheelchair or a chair for home, school, or outdoors, so that the lumbar lordosis can be constantly maintained.
Study NCT03426202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil Oral Tablet
Description: modafinil 200mg
Study NCT03426202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: placebo 200mg
Study NCT04366063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell therapy protocol 1
Description: Cell therapy protocol 1(n=20). Patients will receive two doses of MSCs 100×10e6 (±10%) at Day 0 and Day 2 plus Conventional treatment.
Study NCT04366063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell therapy protocol 2
Description: Patients will receive two doses of MSCs 100×10e6 (±10%)at Day 0 and Day 2, intravenously plus two doses of EVs at Day 4 and Day 6 plus conventional treatment.
Study NCT00582257 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Participation in the registry will consist of adequately completing the family history questionnaire (one per family) the gastric cancer risk factor questionnaire and providing a blood sample for future correlative studies. Registry participants (both Patient/Relative and Control cohorts) will be required to submit tissue (both normal and/or tumor) to create a Tissue and DNA repository. Select participants will be invited to undergo Genetic Counseling, eg. those participants who meet clinical criteria for HDGC.
Study NCT04295954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Intervention
Description: It is an intervention based on Hatha yoga designed specifically to improve dysmenorrhea. This intervention consists of physical postures, also called asanas; meditation and breathing. It begins with a progression of various asanas until reaching the three central postures: cat, cobra and fish. The compensation asanas of these central postures are then performed, and it is closed with a relaxation. The program and Yoga Intervention have been triangulated by experts and piloted afterwards.
Study NCT01837004 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CORTEX
Description: 2-hour sessions for a period of four weeks prior to the initial exercise program start. One hour will be devoted to computerized training (stationary dual-task \& cognitive control training, self-priming, certainty training) whereas the other hour will be devoted to exergaming involving non-stationary, dual-task training.
Study NCT00141739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 0.4 mg/kg per dose \[maximum dose 25 mg\] SC for prophylaxis. To start in the 24 hour time period along with the initiation of the preparative regimen for the stem cell transplant.~Etanercept will be administered twice weekly until day +56 (8 weeks) post transplant.
Study NCT01555788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas for DiaPort system with Zone-MPC algorithm
Description: Artificial pancreas system uses the intraperitoneal route to deliver insulin (through DiaPort) in type 1 diabetic patients treated by basal-bolus insulin and external pumps.
Study NCT01499225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14642 500mg Tab
Description: YH14642 500mg per day(once a day)
Study NCT01499225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14642 500mg Tab
Description: YH14642 1000mg per day(twice a day)
Study NCT01499225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14642 500mg Tab
Description: YH14642 2000mg per day(three times a day)
Study NCT01499225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INSADOL[Zea mays L. extract] 35mg Tab
Description: \[Initiation dose : 4weeks after administraion\] INSADOL\[Zea mays L. extract\] 210mg TAB per day~\[Maintain dose : Between 4weeks and 8weeks after administraion\] INSADOL\[Zea mays L. extract\] 105mg TAB per day~\[Maintain dose : Between 8weeks and 12weeks after administraion\] INSADOL\[Zea mays L. extract\] 105mg TAB per day
Study NCT01499225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DENTISTA[Doxycycline hyclate] 20mg Cap
Description: DENTISTA\[Doxycycline hyclate\] Cap 40mg per day
Study NCT01499225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02877602 — intervention group
Intervention type: DEVICE
Intervention: MRI
Study NCT02877602 — intervention group
Intervention type: DEVICE
Intervention: Transient Elastography
Study NCT02429037 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: radiation therapy will be given at a total dose of 60 Gy by 2.0 Gy/fraction, daily Monday-Friday for 6 weeks.
Study NCT02429037 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation
Description: radiation therapy will be given at a total dose of 60 Gy by 2.0 Gy/fraction, daily Monday-Friday for 6 weeks.
Study NCT02429037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 100 mg/m2 IV on days 1 plus paclitaxel 30 mg/m2 IV on day 1, 8 and 15
Study NCT02429037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 100 mg/m2 IV on days 1 plus paclitaxel 30 mg/m2 IV on day 1, 8 and 15
Study NCT00304512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat HCl
Study NCT06156722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sperm selection by IMSI
Description: Intracytoplasmic morphologically selected sperm injection (IMSI) is a sperm selection method used in intracytoplasmic sperm injection (ICSI)
Study NCT06156722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sperm selection by IMSI and spermslow
Description: Intracytoplasmic morphologically selected sperm injection (IMSI) is a sperm selection method used in intracytoplasmic sperm injection (ICSI) + spermslow
Study NCT03293576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volitional Help Sheet
Description: This brief intervention will last around 20 minutes. The participants and the researcher will read through the list of real-life solutions the participants might find applicable to them. They will then read through the list of situations one by one. The participant will draw a coloured line between the situation and the solution which seems more appropriate to them. The volitional help sheet helps create implementation intentions, which are self-regulatory strategies taking the form of if-then plans (i.e. situation-solution plan).
Study NCT02360319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Any FDA approved antipsychotic agent
Description: Investigators are free to choose the most appropriate treatment for their clients
Study NCT02360319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole long acting injectable formulation
Study NCT03471169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desirable TEG
Description: Change the type and dose of antithrombotic therapy and obtain desirable TEG results.~Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol.
Study NCT03471169 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Undesirable TEG
Description: Don't change the type and dose of antithrombotic therapy and obtain undesirable TEG results. Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol.
Study NCT03297203 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: The investigators will take two kits of blood samples for the group 1, one during the early stage of the septic shock (48 first hours of care) and one during the late stage of the disease (between the fourth and the sixth day). We'll take only one kit of blood samples for the group 2. One kit includes one EDTA tube (5 mL) and five Lithium Heparin tubes (25 mL). The immune mapping will be made by Julien Carvelli, a gold medalist resident, in the framework of a Master 2. The analyses will be made in the laboratory of immunology in the Conception Hospital (Pr Vivier's team).
Study NCT03297203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: The investigators will take two kits of blood samples for the group 1, one during the early stage of the septic shock (48 first hours of care) and one during the late stage of the disease (between the fourth and the sixth day). We'll take only one kit of blood samples for the group 2. One kit includes one EDTA tube (5 mL) and five Lithium Heparin tubes (25 mL). The immune mapping will be made by Julien Carvelli, a gold medalist resident, in the framework of a Master 2. The analyses will be made in the laboratory of immunology in the Conception Hospital (Pr Vivier's team).
Study NCT03123848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat
Description: Participants will receive a FDC tablet of darunavir 800 mg and cobicistat 150 mg orally in the morning of Day 1.
Study NCT01844271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser (LLL)
Description: Comparison of different dosages of a Low Level Laser applied in six different locations of the knee extensor muscles of the lower limb non-dominant before a strenuous exercise.~We performed stretching and warming up of the muscles involved, assessment of muscle pain, withdrawal of blood sample, test muscle function (MVC), application of dose of low level laser designated for each volunteer (0, 2, 6 or 10), performing eccentric contractions protocol in isokinetic dynamometer . After the protocol we evaluated muscle function, the DOMS, and blood analyzes in 1 minute, 1 hour, 24 hours, 48 hours 72 hours and 96 hours.~In a second stage, the optimal dose defined by the first part of the study will be tested in two different powers, 100 and 400mW. The study was repeated in two experimental groups using the optimal dose established and the powers of 100 and 400mW that was randomly distributed in groups.
Study NCT01844271 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low Level Laser (LLL)
Description: Comparison of different dosages of a Low Level Laser applied in six different locations of the knee extensor muscles of the lower limb non-dominant before a strenuous exercise.~We performed stretching and warming up of the muscles involved, assessment of muscle pain, withdrawal of blood sample, test muscle function (MVC), application of dose of low level laser designated for each volunteer (0, 2, 6 or 10), performing eccentric contractions protocol in isokinetic dynamometer . After the protocol we evaluated muscle function, the DOMS, and blood analyzes in 1 minute, 1 hour, 24 hours, 48 hours 72 hours and 96 hours.~In a second stage, the optimal dose defined by the first part of the study will be tested in two different powers, 100 and 400mW. The study was repeated in two experimental groups using the optimal dose established and the powers of 100 and 400mW that was randomly distributed in groups.
Study NCT02274857 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PVI Ablation
Description: Standard PVI procedure without FIRMap.
Study NCT02274857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FIRM-Guided Procedure and PVI
Description: FIRM-guided procedure followed by conventional ablation including PVI.
Study NCT01464827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: ABT-333 tablets
Study NCT00053495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccinia virus: ACAM2000 smallpox vaccine
Description: Group 1 dose: 1.0x10-8th PFU/ml Group 2 dose: 2.0x10-8th PFU/ml Group 3 dose: 1.0x10-7th PFU/ml Group 4 dose: 5.0x10-6th PFU/ml
Study NCT00053495 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: vaccinia virus (calf lymph): Dryvax
Description: Group 5 dose: 1.0x10-8th PFU/ml
Study NCT05379257 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Random dosage and time of furosemide
Description: Random dosage and time of furosemide, using a designated app
Study NCT01361425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methildopa
Description: methildopa, 1,5g/day (500mg 8/8 hours, orally)
Study NCT01361425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 500mg 8/8h, orally
Study NCT03358056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: Mindfulness-based cognitive therapy (MBCT) is a manualized, 8 weeks-group-based training derived from mindfulness-based stress reduction (MBSR) and cognitive-behavioral therapy (CBT). In MBCT participants are trained in how to be more aware of their bodily sensations, thoughts and feelings associated with negative emotional states. Mindfulness exercises and cognitive-behavioral skills are practiced both during the sessions and through homework assignments. The program is structured in 2.30 h group sessions over 8 consecutive weeks.
Study NCT02569437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline (200 mg PO X 1 dose on Day 1, then 100 mg PO daily) for Day 2-20
Study NCT02569437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: oral methylprednisolone: 32 mg x 5 days, 16 mg x 5 days, 8 mg x 10 days
Study NCT02569437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: oral methylprednisolone: 32 mg x 5 days, 16 mg x 5 days, 8 mg x 10 days
Study NCT02569437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nasal saline spray
Description: nasal saline sprays: 2 sprays each nostril three times a day
Study NCT02569437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flonase
Description: daily nasal steroid sprays (Flonase, 2 sprays each nostril daily).
Study NCT02569437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flonase
Description: daily nasal steroid sprays (Flonase, 2 sprays each nostril daily).
Study NCT02569437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: placebo pill to match doxycycline